Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ritonavir
|
| gptkbp:activities |
inhibits HIV protease
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:brand |
Reyataz
|
| gptkbp:class |
protease inhibitor
|
| gptkbp:clinical_trial |
Phase II
Phase III HIV-1 infection treatment-experienced patients |
| gptkbp:contraindication |
severe liver disease
concurrent use of certain medications hypersensitivity to atazanavir |
| gptkbp:counseling_services |
take with food
report any signs of liver problems adherence to therapy is crucial avoid antacids close to dosing |
| gptkbp:discovered_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:dosage_form |
300 mg tablet
150 mg tablet |
| gptkbp:formulation |
gptkb:beer
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Atazanavir
|
| gptkbp:interacts_with |
gptkb:rifampin
antacids H2-receptor antagonists |
| gptkbp:is_available_in |
many countries
|
| gptkbp:is_monitored_by |
liver function tests
viral load C D4 count |
| gptkbp:is_used_for |
treatment of HIV
|
| gptkbp:lifespan |
7 to 11 hours
|
| gptkbp:marketed_as |
Reyataz
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
highly protein-bound
oral bioavailability is variable |
| gptkbp:requires |
prescription only
|
| gptkbp:side_effect |
headache
nausea jaundice diarrhea rash increased cholesterol hyperbilirubinemia fat redistribution |
| gptkbp:status |
ongoing studies
|
| gptkbp:storage |
room temperature
protected from light |